FDA lays the ham­mer on Emer­gen­t's Bal­ti­more plant af­ter J&J de­ba­cle, halt­ing all pro­duc­tion in un­usu­al move

Emer­gent BioSo­lu­tions has had a tough month: First, the CD­MO ru­ined 15 mil­lion dos­es of J&J’s Covid-19 vac­cine in March and then suf­fered the ig­nominy of the FDA seiz­ing the reins. Now, as the agency re­ceives a full ac­count­ing of the site’s prob­lems, Emer­gent has slammed the brakes on all pro­duc­tion at the FDA’s be­hest.

Emer­gent will cease man­u­fac­tur­ing at its Bal­ti­more plant un­til the FDA’s in­spec­tion and re­me­di­a­tion of any find­ings is com­plete, the com­pa­ny said in a state­ment. Emer­gent will al­so quar­an­tine ex­ist­ing ma­te­ri­als that have al­ready been man­u­fac­tured. That stop­page start­ed on Fri­day, four days af­ter the ini­ti­a­tion of the FDA’s in­spec­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER